Sign In
Buy ATRC
$37.76
-2.39 (-5.95%)
At Close: Jul 31, 2026
Are Medical Stocks Lagging AtriCure (ATRC) This Year?
10:41am, Monday, 08'th Dec 2025
Here is how AtriCure (ATRC) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?
04:24pm, Saturday, 29'th Nov 2025
AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000.
Wall Street Analysts Believe AtriCure (ATRC) Could Rally 36.3%: Here's is How to Trade
10:56am, Tuesday, 25'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 36.3% in AtriCure (ATRC). While the effectiveness of this highly sought-after metric is questionable, the posit
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
10:41am, Thursday, 20'th Nov 2025
Here is how AtriCure (ATRC) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
AtriCure to Participate in the Piper Sandler 37th Annual Healthcare Conference
08:00am, Tuesday, 18'th Nov 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
8,681 Shares in AtriCure, Inc. $ATRC Purchased by Campbell & CO Investment Adviser LLC
03:51am, Tuesday, 18'th Nov 2025
Campbell and CO Investment Adviser LLC purchased a new stake in AtriCure, Inc. (NASDAQ: ATRC) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional invest
AtriCure, Inc. (ATRC) Presents at UBS Global Healthcare Conference 2025 Transcript
04:41pm, Monday, 10'th Nov 2025
AtriCure, Inc. ( ATRC ) UBS Global Healthcare Conference 2025 November 10, 2025 2:00 PM EST Company Participants Angela Wirick - Chief Financial Officer Michael H. Carrel - CEO, President & Director C
AtriCure (ATRC) Loses 13.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Friday, 07'th Nov 2025
The heavy selling pressure might have exhausted for AtriCure (ATRC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings (Revised)
03:21am, Thursday, 06'th Nov 2025
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics comp
Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 04'th Nov 2025
Here is how AtriCure (ATRC) and Cabaletta Bio, Inc. (CABA) have performed compared to their sector so far this year.
AtriCure, Inc. (ATRC) Q3 2025 Earnings Call Transcript
11:16pm, Wednesday, 29'th Oct 2025
AtriCure, Inc. ( ATRC ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Michael H. Carrel - CEO, President & Director Angela Wirick - Chief Financial Officer Conference Call Pa
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q3 Earnings
06:31pm, Wednesday, 29'th Oct 2025
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics comp
AtriCure (ATRC) Reports Q3 Loss, Beats Revenue Estimates
06:11pm, Wednesday, 29'th Oct 2025
AtriCure (ATRC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.17 per share a year ago.
AtriCure Reports Third Quarter 2025 Financial Results; Raises Financial Outlook for 2025
04:01pm, Wednesday, 29'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure Announces the First Patient Treated in the BoxX-NoAF Clinical Trial
08:00am, Tuesday, 28'th Oct 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
